PepGen ends all work on Duchenne muscular dystrophy after lead asset fails to raise dystrophin levels
Months after causing safety concerns that led the FDA to hit a related trial with a clinical hold, a phase 2 trial of PepGen’s lead Duchenne muscular dystrophy (DMD) candidate has resulted in limited evidence for any clinical benefit, prompting the Boston biotech to scrap the asset and end all DMD R&D activities.
Months after causing safety concerns that led the FDA to hit a related trial with a clinical hold, a phase 2 trial of PepGen’s lead Duchenne muscular dystrophy (DMD) candidate has resulted in limited evidence for any clinical benefit, prompting the Boston biotech to scrap the asset and end all DMD R&D activities.
